A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Suspension Injection of Investigational Capsid Inhibitors Compared to Placebo in Healthy Adults

HIV Infections Clinical Trial

Official title:

A Phase 1 Double-Blind (Sponsor-unblinded), Placebo-Controlled, Randomized, Single Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Parenterally Administered Suspension of Investigational Capsid Inhibitors in Healthy Adults

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06012136
• Other study ID #: 218306
• Status: Recruiting
• Phase: Phase 1
• Start date: August 24, 2023
• Est. completion date: May 5, 2026

Study information

• Verified date: January 2024
• Source: ViiV Healthcare
• Contact: US GSK Clinical Trials Call Center
• Phone: 877-379-3718
• Email: GSKClinicalSupportHD[@]gsk.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary purpose of the study is to investigate safety and tolerability following single ascending subcutaneous (SC) and intramuscular (IM) doses of capsid inhibitors in healthy participants. The study will also describe the pharmacokinetics following single ascending SC and IM doses of capsid inhibitors in healthy participants.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 160
• Est. completion date: May 5, 2026
• Est. primary completion date: May 5, 2026
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• Participants who are overtly healthy.
• Participants who are negative on a single test for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (approved molecular polymerase chain reaction (PCR), point of care test), performed on the day of admission (Day -1). A negative result is required prior to the administration of study intervention on Day 1.
• Male or female participants of non-childbearing potential.
• Capable of giving signed informed consent.

Exclusion Criteria:

• History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, neurological or psychiatric disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention or interfering with the interpretation of data.
• Abnormal blood pressure.
• Lymphoma, leukemia, or any malignancy within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years.
• Breast cancer within the past 10 years.
• Current or chronic history of liver disease or known hepatic or biliary abnormalities.
• History of sensitivity to any of the study interventions, a history of drug allergy or other allergy that contraindicates their participation.
• The participant has an underlying skin disease or disorder that would interfere with assessment of injection sites.
• Participants considered to have insufficient musculature to allow safe capsid inhibitor intramuscular (gluteus medius) administration.
• History of or on-going high-risk behaviours that may put the participant at increased risk for HIV.
• Past or intended use of over-the-counter or prescription medication including herbal medications.
• Current enrollment or recent past participation in another investigational study.
• Exposure to more than 4 investigational products within 12 months prior to dosing.
• Alanine transaminase (ALT) =1.5x upper limit of normal (ULN), Total bilirubin =1.5x ULN (isolated total bilirubin >1.5xULN), and/or estimated creatinine clearance (eGFR) of <60 millilitre per minute (mL/min)/1.73 square meter (m^2).
• History of or current infection with hepatitis B or hepatitis C.
• Positive SARS-CoV-2 polymerase chain reaction test, having signs and symptoms, or having contact with known coronavirus disease 2019 (COVID-19) positive person/s in the 14 days prior to inpatient admission.
• Use of tobacco or nicotine-containing products, regular alcohol consumption and/or regular use of known drugs of abuse.
• Positive HIV antibody/antigen test.
• Abnormal electrocardiogram (ECG) parameters.
• Evidence of previous myocardial infarction, any conduction abnormality, any significant arrhythmia, non-sustained or sustained ventricular tachycardia, and/or sinus pauses (>3 seconds).
• The participant has a tattoo or other dermatological condition overlying the location of injection or a prior history of silicone implants or fillers (gluteal) which may interfere with interpretation of injection site reactions or administration of study product.

Related Conditions & MeSH terms

• HIV Infections

Intervention

Drug:
• VH4004280
VH4004280 will be administered.
• Placebo
Placebo will be administered.
• VH4011499
VH4011499 will be administered.

Locations

Country	Name	City	State
United States	GSK Investigational Site	Austin	Texas
United States	GSK Investigational Site	Las Vegas	Nevada

Sponsors (1)

Lead Sponsor	Collaborator
ViiV Healthcare

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants with Adverse Events (AEs) as per Severity	An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. Severity of Adverse Event will be assessed using Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS). DAIDS grading scale is used to grade the toxicity associated with injection site reactions (ISR) including injection site pain (or tenderness), erythema (or redness), induration (or swelling), and pruritis. The toxicity level is graded from grade 1(lowest toxicity) to 4 (highest toxicity). Higher grade indicates higher toxicity.	Up to Week 52
Primary	Absolute Values of Liver Chemistry Parameters: Total Bilirubin and Direct Bilirubin (micromoles per liter [umol/L])		Up to Week 52
Primary	Change from Baseline in Liver Chemistry Parameters: Total Bilirubin and Direct Bilirubin (umol/L)		Baseline (Prior to Day 1) and up to Week 52
Primary	Number of Participants with Maximum Toxicity Grade Change from Baseline in Liver Chemistry Parameters: Total Bilirubin, Direct Bilirubin, Alkaline Phosphatase, Aspartate Aminotransferase (AST), and Alanine Aminotransferase (ALT)		Up to Week 52
Primary	Absolute Values of Liver Chemistry Parameters: Alkaline Phosphatase, Aspartate Aminotransferase (AST), and Alanine Aminotransferase (ALT) (International Units per liter)		Up to Week 52
Primary	Change from Baseline in Liver Chemistry Parameters: Alkaline Phosphatase, AST, and ALT (International Units per liter)		Baseline (Prior to Day 1) and up to Week 52
Primary	Number of Participants with Injection Site Reactions (ISR) AE by Grade Using the DAIDS Grading Scale	DAIDS grading scale is used to grade the toxicity associated with injection site reactions (ISR) including injection site pain (or tenderness), erythema (or redness), induration (or swelling), and pruritis. The toxicity level is graded from grade 1(lowest toxicity) to 4 (highest toxicity). Higher grade indicates higher toxicity.	Up to Week 52
Primary	Duration of ISR (Days) AE	Duration of ISR will be assessed as the time up to which a reaction related to injection site event is persistent.	Up to Week 52
Primary	Area Under the Plasma-concentration Time curve from Time Zero to Infinity (AUC0-inf) of VH4004280		Up to Week 52
Primary	Area Under the Plasma-concentration Time curve from Time Zero to Infinity (AUC0-inf) of VH4011499		Up to Week 52
Primary	Maximum Observed Plasma Concentration (Cmax) of VH4004280		Up to Week 52
Primary	Maximum Observed Plasma Concentration (Cmax) of VH4011499		Up to Week 52
Primary	Time of Maximum Observed Plasma Concentration (tmax) of VH4004280		Up to Week 52
Primary	Time of Maximum Observed Plasma Concentration (tmax) of VH4011499		Up to Week 52
Primary	Apparent Terminal Half-life (t1/2) of VH4004280		Up to Week 52
Primary	Apparent Terminal Half-life (t1/2) of VH4011499		Up to Week 52